Sosei Group Corp at JPMorgan Healthcare Conference (Virtual) Transcript
Good morning. My name is Chris Cargill, Chief Financial Officer at Sosei Group Corporation. Today, I will give you a brief overview of our technology, platform, core capabilities, business model, pipeline programs and an insight into our strategy.
Please turn to Slide 3. Now firstly, a quick introduction for those that are new to our company. We are a world-leading team of drug hunters, and we're specifically focused on G protein-coupled receptors or GPCRs. We apply a proprietary technology called StaR, which stands for Stabilized Receptor, and leverage our structure-based drug design platform infrastructure to discover novel and best-in-class small molecule therapeutics.
We are an Anglo-Japanese company, publicly listed in Japan. However, our main R&D campus is located in Cambridge, U.K., and this is where 80% of our R&D employees are based. Our ambition is to become one of Japan's global biotechnology and drug discovery champions.
We are a science-led organization. Over 75% of our staff have a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |